This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial
We measure cyclosporine and tacrolimus levels. But don’t bother with mycophenolate levels - why is it? Is it too difficult? Does it not matter? NephJC tackles a different kind of study this time - a literature review, albeit conducted systematically.
We complain about the quality of kidney research but is there any meat there? Join us this week as we look at Chatzimanouil’s recent examination of the nephrology literature.
We will be discussing a systematic review on treatment options for uremic pruritis. Such a simple symptom can be so bothersome, and is so common. Join us as we discuss the options on Sep 27